India Eyes Stricter Cough Syrup Labels for Young Children

India's drug regulator is considering prominent red warnings on cough syrup bottles, advising against use in children under 4. This follows concerns over pediatric cough medicine use and prior restrictions on fixed-dose combinations.

A subsequent grievance regarding the ongoing prescribing of cough medicine to babies listed below two years was checked out by an internal technological board of the Central Drugs Criterion Control Organisation (CDSCO) in April 2026.

The proposition, which has actually been placed prior to the Drugs Consultative Committee (DCC), calls for the advising to be shown in red on the bottle label. It additionally suggests a pictorial representation of school-age youngsters to strengthen that the medication is suggested for older youngsters and dissuade its usage in infants and toddlers, according to the ET report.

Concerns Prompt Regulatory Review

The step comes in the middle of ongoing problems over making use of coughing and cool medications amongst children. In October 2025, the Directorate General of Health And Wellness Providers (DGHS) had encouraged that coughing and cool medicines need to be prescribed and given deliberately in paediatric treatment. It especially advised against recommending or dispensing such medicines to children listed below two years old.

Cough syrup bottles might quickly lug a noticeable caution against their use in kids below 4 years old, with India’s drug regulatory authority taking into consideration modifications to the labelling demands for such medicines, The Economic Times reported on Saturday.

Proposed Labeling Changes

The suggested wider labelling adjustment comes shortly after the federal government enforced restrictions on all fixed-dose mixes (FDCs) containing chlorpheniramine maleate and phenylephrine hydrochloride for use in youngsters below four years.

The committee recommended getting in touch with the Indian Council of Medical Study (ICMR) on whether it had any kind of proposals worrying cough medicine in the paediatric population. It additionally suggested stakeholder appointments on the regulatory and advertising feasibility of modifications to cough-syrup labelling.

Further Consultations and Restrictions

In an August 22 alert, the wellness ministry stated manufacturers of these FDCs have to present a warning that they should not be used in children below 4 years of age on the label, plan insert and advertising literary works. The restriction adhered to suggestions from a professional board and the Drugs Technical Board Of Advisers.